BlueLinx Announces Third-Quarter Results
Nov 10, 2016 12:01 pm UTC| Business
– Net income of $15.0 million; highest quarter net income since 2004 –– Diluted earnings per share of $1.68 –– Debt principal reduction of $87.2 million from Q3 2015 – ATLANTA, Nov. 10, 2016 -- BlueLinx Holdings Inc....
NeuroDerm Announces Third Quarter 2016 Financial Results
Nov 10, 2016 12:01 pm UTC| Business
REHOVOT, Israel, Nov. 10, 2016 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter...
ZIOPHARM to Present at the Jefferies 2016 London Healthcare Conference
Nov 10, 2016 12:01 pm UTC| Business
BOSTON, Nov. 10, 2016 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursday,...
ZIOPHARM to Present at the Jefferies 2016 London Healthcare Conference
Nov 10, 2016 12:01 pm UTC| Business
BOSTON, Nov. 10, 2016 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer, will present at the Jefferies 2016 London Healthcare Conference on Thursday,...
Recro Pharma Reports Third Quarter 2016 Financial Results
Nov 10, 2016 12:01 pm UTC| Business
Announced Positive Phase III Results from Pivotal Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam Following Mini Abdominoplasty Surgery Ongoing; Top-line Data Expected by Year...
Recro Pharma Reports Third Quarter 2016 Financial Results
Nov 10, 2016 12:01 pm UTC| Business
Announced Positive Phase III Results from Pivotal Trial of IV Meloxicam Following Bunionectomy Surgery Pivotal Phase III Trial of IV Meloxicam Following Mini Abdominoplasty Surgery Ongoing; Top-line Data Expected by Year...
VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
Nov 10, 2016 12:01 pm UTC| Business
TEL AVIV, Israel, Nov. 10, 2016 -- VBL Therapeutics (NASDAQ:VBLT), today reported financial results and provided a business update for the third quarter and nine month period ended September 30, 2016. “We continue to...